Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

PHASE3TerminatedINTERVENTIONAL
Enrollment

18,695

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Cardiovascular Disease
Interventions
DRUG

Rimonabant

Tablet, oral administration

DRUG

Placebo (for Rimonabant)

Tablet, oral administration

Trial Locations (43)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Buenos Aires

sanofi-aventis Australia & New Zealand administrative office, Macquarie Park

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Shangaï

Sanofi-Aventis Administrative Office, Bogotá

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Hørsholm

Sanofi-Aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Athens

Sanofi-Aventis Administrative Office, Hong Kong

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Mumbai

Sanofi-Aventis Administrative Office, Dublin

Sanofi-Aventis Administrative Office, Netanya

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Kuala Lumpur

Sanofi-Aventis Administrative Office, México

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Lysaker

Sanofi-Aventis Administrative Office, Lima

Sanofi-Aventis Administrative Office, Makati City

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Porto Salvo

Sanofi-Aventis Administrative Office, Bucharest

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Singapore

Sanofi-Aventis Administrative Office, Midrand

Sanofi-Aventis Administrative Office, Seoul

Sanofi-Aventis Administrative Office, Madrid

Sanofi-Aventis Administrative Office, Bromma

Sanofi-Aventis Administrative Office, Geneva

Sanofi-Aventis Administrative Office, Taipei

Sanofi-Aventis Administrative Office, Bangkok

Sanofi-Aventis Administrative Office, Mégrine

Sanofi-Aventis Administrative Office, Istanbul

Sanofi-Aventis Administrative Office, Guildford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00263042 - Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes | Biotech Hunter | Biotech Hunter